Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Oncologists Highlight Key Takeaways and Abstracts From the 2025 ESMO GI Cancers Congress

July 11th 2025

Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.

Targeted Therapies Broaden Treatment Options for CDK4/6 Inhibitor–Resistant, HR+ Breast Cancer

July 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses the importance of optimizing endocrine-based therapies in hormone receptor–positive metastatic breast cancer.

HER2DX Assay Predicts pCR Following Neoadjuvant THP in HER2+ Breast Cancer

July 10th 2025

HER2DX genomic scoring predicted pCR after neoadjuvant THP in a high-risk subgroup of patients with HER2-positive early breast cancer.

Studies Highlight Real-World Gaps in Third-Line mCRC and Evolving Role of Molecular Profiling in GI NETs

July 10th 2025

Rocío García-Carbonero, MD, discusses safety challenges in third-line mCRC and the role of molecular testing in aggressive GI neuroendocrine tumors.

Dr Vogel on the European Commission’s Marketing Authorization of Zanidatamab for HER2+ Biliary Tract Cancer

July 9th 2025

Dr Arora on A Retrospective Analysis of Temporal Trends to Assess MCL Incidence From 2000-2021

July 9th 2025

Ruby Arora, MD, discusses the design of a retrospective analysis of temporal trends in MCL incidence from 2000 to 2021.

Real-World ctDNA Positivity Predicts Poorer Outcomes in Early Breast Cancer

July 9th 2025

Real-world analysis showed ctDNA positivity was associated with higher recurrence risk and reduced overall survival in early breast cancer.

Bexobrutideg Earns EMA Orphan Drug Designation for Waldenström Macroglobulinemia

July 9th 2025

Bexobrutideg received European Medicines Agency orphan drug designation for Waldenström macroglobulinemia.

Post Hoc Data Highlight Utility of Fruquintinib Across Metastatic Subgroups in Refractory mCRC

July 9th 2025

Rocío García-Carbonero, MD, discusses findings from a subgroup analysis of FRESCO-2 with fruquintinib in refractory mCRC.

Padeliporfin Vascular Targeted Photodynamic Therapy Safely Produces High Response Rates in Low-Grade Upper Tract Urothelial Cancer

July 8th 2025

Padeliporfin vascular targeted photodynamic therapy was highly active with a tolerable safety profile in low-grade upper tract urothelial cancer.

PAOLA-1 Analysis Shows PD-L1 Expression Correlates With HRD Positivity in High-Grade Serous Ovarian Cancer

July 7th 2025

PD-L1 expression was more common in HRD-positive high-grade serous ovarian cancer, indicating potential prognostic value in newly diagnosed cases.

Dr Finn on Adding Tiragolumab to Atezolizumab and Bevacizumab in Locally Advanced or Metastatic HCC

July 5th 2025

Richard Finn, MD, discusses the addition of tiragolumab to atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

Dr García-Carbonero on Outcomes With Fruquintinib in R/R mCRC by Metastatic Sites

July 5th 2025

Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.

Dr Janjigian on PROs for Perioperative Durvalumab Plus FLOT in Gastric/GEJ Adenocarcinoma

July 4th 2025

Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.

Dr O’Reilly on the Rapidly Evolving Role of Local Therapy in Metastatic Pancreatic Cancer

July 3rd 2025

Eileen M. O’Reilly, MD, discusses the rapidly evolving role of local therapy in the management of advanced/metastatic pancreatic cancer.

Dr Weinberg on the Efficacy of BXCL701 Plus Pembrolizumab in Pretreated, Metastatic PDAC

July 3rd 2025

Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.

Dr Cheng on the Safety and Efficacy of Irpagratinib Plus Atezolizumab in Advanced HCC

July 3rd 2025

Qi Cheng, MD, discusses the safety and efficacy of irpagratinib plus atezolizumab in advanced hepatocellular carcinoma.

Dr Cardoso on the Effect of Elinzanetant on Vasomotor Symptoms in HR+ Breast Cancer

July 3rd 2025

Fatima Cardoso, MD, MSc, FESMO, discusses the use of elinzanetant for vasomotor symptoms in women receiving endocrine therapy for HR+ breast cancer.

Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD

July 2nd 2025

Drs Park and Malla discuss therapeutic options for patients with metastatic colorectal cancer, particularly in the third-line setting and beyond.

Dr Riechelmann on the Management of Refractory Carcinoid Syndrome in Functional GI NETs

July 2nd 2025

Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.